Methods Of Identification And Diagnosis Of Lung Diseases Using Makes a Small Case for Better Timing

What changes in this design

Someone might assume that diagnosing a lung disease depends on gathering medical information. How this is ordinarily done for these conditions, and what any measurement measures, is not stated.

This record describes using biomarkers, either separately or in combinations, with an organized way of grouping measurements. It also includes kits containing agents for detecting the biomarkers.

The approach can consider more than one biomarker at a time and includes a kit-based part. Its accuracy, the exact measurements, and how its results guide care are not stated.

142,000 patients

In 2026, a 142,000-patient British trial put a blood test for several cancers through the question that matters most: would finding a signal earlier save lives? It did not meet that key goal. The test's maker pointed to signs in aggressive cancers, while independent researchers called the proposed benefits speculative. That gap is the one I keep returning to. A promising signal is not a life-saving screening program.

Lung cancer gives that question urgency. U.S. estimates for 2026: 229,410 new lung and bronchus cancer cases and 124,990 deaths. Fifty-one percent are found after the disease has spread, when five-year relative survival is 10.5 percent. A vial of blood before a definitive diagnosis is a temptation I understand.

An Indiana filing

That is the setting for US20260253683A1, published on August 27. It comes from Lung Cancer Proteomics LLC, a small Indiana assignee with priority in this family from April 29, 2011. Filed in 2025, the new application continues an issued patent. That chain is not proof that the test works, as I read it. The chain reads to me as evidence that a hard clinical question can outlast patent paperwork.

Claim 1 has been canceled. The claims that remain describe measuring a set of proteins in plasma, including TNF Receptor 1, TNF Receptor 2, IL-2, PDGFBB, and MIG, then adding at least one more named biomarker. Those measurements go into a support vector machine, Random Forest, or AdaBoost classifier trained on stored vectors, for people at risk of non-small cell lung cancer. That is a method claim, not a report of outcomes in people.

Thirty-three proteins

A related application makes the intended use plainer. It describes a 33-marker plasma panel, with Random Forest preferred, for use after a CT scan finds a lung nodule but cannot tell whether it is cancer. It sets out sensitivity and specificity targets from 0.7 to 0.98. Those are goals in an application, not demonstrated performance. Goals in an application shouldn't become a result merely because they sit beside a list of proteins, as we see it.

That distinction matters after imaging. A person with a suspicious nodule needs help deciding whether to wait, scan again, biopsy, or operate. The wrong nudge can lead to an invasive procedure on a benign nodule; a missed cancer can defer care. A blood test may improve that decision, but the patent cannot establish it by naming a panel and an algorithm.

12,208 Scottish volunteers

The closest trial I found shows both hope and restraint. In Scotland, 12,208 high-risk people were offered an autoantibody blood test followed by imaging. The intervention group had fewer late-stage diagnoses: 58.9 percent, versus 73.2 percent in the control group. Yet overall sensitivity was 32.1 percent, and after two years, lung-cancer deaths were 17 versus 24, a difference that was not statistically significant.

That trial did not evaluate this plasma panel, and I would not use it to pronounce the patent futile. It shows why earlier diagnosis is only a step toward what patients care about. The researchers could not separate the blood test's contribution from CT alone. In a broader 2025 review, AHRQ found no controlled studies showing that blood-based multicancer screening improves outcomes. Across 20 studies, sensitivity ranged from 0.095 to 0.998. That is not a verdict, but it warns against treating biomarker detection as settled care.

Laboratory-developed tests

Meanwhile, the rules for laboratory-developed tests moved backward. A federal court vacated the FDA's 2024 final rule on March 31, 2025, and the FDA reverted it that September. The ruling did not make any test less or more accurate. It left laboratory-developed tests in a status quo where some can be offered without federal clearance. This patent does not tell us what product, if any, will follow. It arrives while the regulatory route for laboratory-developed tests remains unsettled.

What would have to be true

The standard, I think, is demanding and simple. Before this filing should change a decision, its panel must detect cancer while cure is still plausible, add useful information beyond CT and ordinary risk factors, avoid needless procedures, and improve something patients can feel - preferably mortality, not only a classifier score. It must do so in the people who would receive it, not merely in stored samples. Until then, this is a patent inside an unfinished clinical argument.

Sources

Reporting for this piece drew on the published filing and the references below.

1. US20260253683A1 - Methods Of Identification And Diagnosis Of Lung Diseases Using Classification Systems And Kits Thereof
2. Full text for US20260253683A1
3. US20240087754A1 - Plasma based protein profiling for early stage lung cancer diagnosis
4. Cancer Stat Facts: Lung and Bronchus Cancer
5. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging
6. Blood-Based Tests for Multiple Cancer Screening: A Systematic Review
7. Laboratory Developed Tests

The record, briefly. US20260253683A1, “Methods Of Identification And Diagnosis Of Lung Diseases Using Classification Systems And Kits Thereof” The invention provides biomarkers and biomarker combinations for diagnosing lung diseases, including non-small cell lung cancer and reactive airway disease, using classification-system measurements and kits containing detection agents.

Identity details. The saved title-page transcription needs review, so names are not repeated here. Check the official published title page.

More angles on this

• A Handoff Worth Watching: Fragment-Based Drug Design With an Assistant at the BenchAnother reading from the same G16B classification family, bioinformatics.
• Measurement And Analysis Method For Detecting And Quantifying Makes a Small Case for Better TimingAnother reading from the same G16B classification family, bioinformatics.
• CPC G16B: BioinformaticsThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
• CPC G16H: Healthcare informaticsThe official classification family this record was filed into, published in the USPTO Cooperative Patent Classification scheme.
• Methods For Treatment Of Thyroid Cancer Treats the Relationship as the PointAnother reading from the neighbouring G16Z classification family, information and communication technology [ict] specially adapted for specific application fields.

Read around this one:Public patent recordUSPTO published figure